Blueprint Medicines Corp reports results for the quarter ended in June - Earnings Summary

Blueprint Medicines

02/08/2023 14:31

* Blueprint Medicines Corp  BPMC.OQ  reported a quarterly
adjusted
loss of $2.19​​ per share for the quarter ended in June. The
mean expectation of seventeen analysts for the quarter was for a
loss of $2.54 per share.
    * Revenue rose 57.5% to $57.57 million from a year ago;
analysts
expected $45.47 million. 
    * Blueprint Medicines Corp's reported EPS for the quarter
was a
loss of $2.19​.
    * The mean earnings estimate of analysts had risen by
about 5.3%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Blueprint Medicines Corp shares had risen by 1.5% this
quarter and gained 46.4% so far this year.
    * The company reported a quarterly loss of $132.79 million.
    * Wall Street's median 12-month price target for Blueprint
Medicines Corp is $80.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 4
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 2 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -2.54          -2.19          Beat
 Mar. 31 2023      -2.67          -2.15          Beat
 Dec. 31 2022      -2.65          -2.65          Met
 Sep. 30 2022      -2.49          -2.23          Beat